Patents by Inventor Maqbool A. Siddiqui

Maqbool A. Siddiqui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • C4?-substituted-2-deoxyadenosine analogs and methods of treating HIV
    Patent number: 8513214
    Abstract: The invention provides for novel 2-Deoxyadenosine compounds, which can treat HIV infection at low cytotoxicity values. Substitution at the 4?-position provided compounds which demonstrated low cytotoxicity values in an ATP-based cytotoxicity assay.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: August 20, 2013
    Assignee: The United States of America as Represented by the Secretary of the Dept. of Health and Human Services
    Inventors: Bao-Han C. Vu, Maqbool A. Siddiqui, Victor E. Marquez, Stephen H. Hughes, Paul L. Boyer
  • C4'-SUBSTITUTED-2-DEOXYADENOSINE ANALOGS AND METHODS OF TREATING HIV
    Publication number: 20110190226
    Abstract: The invention provides for novel 2-Deoxyadenosine compounds, which can treat HIV infection at low cytotoxicity values. Substitution at the 4?-position provided compounds which demonstrated low cytotoxicity values in an ATP-based cytotoxicity assay.
    Type: Application
    Filed: November 10, 2008
    Publication date: August 4, 2011
    Inventors: Bao-Han C. Vu, Maqbool A. Siddiqui, Victor E. Marquez, Stephen H. Hughes
  • Conformationally locked nucleoside analogues
    Patent number: 5869666
    Abstract: Conformationally locked 4',6'-cyclopropane-fused carboxylic nucleoside analogues. The compounds are prepared by condensing a cyclopropane-fused carbocyclic allylic alcohol with substituted purine or pyrimidine bases. The condensation products are then modified to produce the adenosine, guanosine, cytidine, thymidine, and uracil nucleoside analogues. The compounds are therapeutically useful as antimetabolites, or in the preparation of anti-metabolic agents.
    Type: Grant
    Filed: March 14, 1997
    Date of Patent: February 9, 1999
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Victor E. Marquez, Juan B. Rodriguez, Marc C. Nicklaus, Joseph J. Barchi, Jr., Maqbool A. Siddiqui
  • Conformationally locked nucleoside analogs as antiherpetic agents
    Patent number: 5840728
    Abstract: A method for treatment of herpes virus infection by administering an effective virus-inhibiting amount of a cyclopropanated carbocyclic 2'-deoxynucleoside to an individual in need thereof. The nucleoside analogs are effective against herpes simplex virus types 1 and 2; Epstein-Barr Virus and human cytomegalovirus.
    Type: Grant
    Filed: August 7, 1997
    Date of Patent: November 24, 1998
    Assignee: United States of America as represented by the Department of Health and Human services
    Inventors: Victor E. Marquez, Marc C. Nicklaus, Joseph J. Barchi, Jr., Juan B. Rodriguez, Maqbool Siddiqui
  • Conformationally locked nucleoside analogues
    Patent number: 5629454
    Abstract: Conformationally locked 4',6'-cyclopropane-fused carbocyclic nucleoside analogues. The compounds are prepared by condensing a cyclopropane-fused carbocyclic allylic alcohol with substituted purine or pyrimidine bases. The condensation products are then modified to produce the adenosine, guanosine, cytidine, thymidine and uracil nucleoside analogues. The compounds are therapeutically useful as antimetabolites, or in the preparation of anti-metabolic agents.
    Type: Grant
    Filed: September 23, 1994
    Date of Patent: May 13, 1997
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Victor E. Marquez, Juan B. Rodriguez, Marc C. Nicklaus, Joseph J. Barchi, Jr., Maqbool A. Siddiqui
  • 2'-fluorofuranosyl derivatives and novel method of preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides
    Patent number: 5336764
    Abstract: A compound has the formula ##STR1## wherein R is selected from the group consisting of (C.sub.7 -C.sub.20)aroyl, (C.sub.6 -C.sub.20)aryl, aralkyl and alkylaryl, and (C.sub.1 -C.sub.10)alkyl-di(C.sub.6 -C.sub.20)aryl Si, R' is selected from the group consisting of (C.sub.1 -C.sub.10)alkyl, (C.sub.7 -C.sub.20)aroyl and (C.sub.2 -C.sub.12)acyl, all of which may be further substituted with O, S, N or alkyl, and R'" is selected from the group consisting of halogen, (C.sub.1 -C.sub.10)alkoxy, (C.sub.1 -C.sub.10)acyloxy, O-methane-sulfonyl and O-p-toluenesulfonyl. A composition of matter comprises 0.001 to 99.999 wt % of the above compound.
    Type: Grant
    Filed: October 29, 1992
    Date of Patent: August 9, 1994
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Victor E. Marquez, John S. Driscoll, Ronald J. Wysocki, Jr., Maqbool A. Siddiqui